All posts by: Michael Zand

About Michael Zand

Mid-Day Market Update: SCANA Climbs Following Merger With Dominion Energy; Crispr Therapeutics Shares Slide – Benzinga

Continue reading

2018-01-03 NEWS

Mid-Day Market Update: SCANA Climbs Following Merger With Dominion Energy; Crispr Therapeutics Shares Slide
Benzinga
… 9 percent to $12.14 after the company reported the termination of its merger deal with China’s Ant Financial, due to the CFIUS rejected the companies proposals related to protecting personal data. Shares of Atara Biotherapeutics Inc (NASDAQ: ATRA

and more »

Continue reading

2018-01-03 NEWS

Investor’s Business Daily

Spark Therapeutics Prices First-Ever Gene Therapy At $850,000 …
Investor’s Business Daily
Spark and GlaxoSmithKline are pricing the world’s first approved gene therapies at prices approaching $1 million.

and more »

Continue reading

2018-01-03 NEWS

FiercePharma

Inovio Amends Chinese Deal for Immunotherapy, Shares Up
Nasdaq
Shares of Inovio Pharmaceuticals, Inc. INO ) have gained about 13.32%, after the company announced that it has entered into an amended agreement with Chinese partner – ApolloBio Corporation. Per the amended agreement, ApolloBio will have the exclusive
Inovio grabs $23M through HPV immunotherapy licensing deal with China’s ApolloBioFiercePharma
Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in …Markets Insider
Could Inovio Pharmaceuticals, Inc. (INO) Rise Even More? The Stock Had Another Big Increase TodayFrisco Fastball
Market Exclusive
all 50 news articles »
Continue reading

2018-01-03 NEWS

Ovarian Cancer News Today

Aivita Launches Phase 2 Trial of Dendritic Cell Immunotherapy for Ovarian Cancer
Ovarian Cancer News Today
Aivita Biomedical has initiated a Phase 2 trial of a new kind of dendritic cell immunotherapy for certain types of ovarian cancer. The therapy uses a patient’s own dendritic cells, which are boosted to fight the tumor by exposure to tumor proteins. The

Continue reading

2018-01-03 NEWS

IDbyDNA, Locus Biosciences Partner on CDx for CRISPR …
GenomeWeb
The next-generation sequencing test will be used to select patients for a clinical trial of Locus’ Pseudomonas aeruginosa antimicrobial product.
Locus Biosciences and IDbyDNA Partner to Develop Companion …PR Newswire (press release)

all 2 news articles »

Continue reading

2018-01-03 NEWS

Brainstorm Health: Health Industry Drivers, Spark Blindness Drug Price, ALS Gene Therapy
Fortune
Good morning, Dailies, and thank you for beginning another year with us in your mailbox. As I mentioned in yesterday’s note, I spent much of the holiday break pondering the big ideas and trends that are going to drive the healthcare revolution in the

and more »